Pharma & Healthcare He couldn't think straight for days, he says, so he gave it up. Kibar owns a third of the company, which would give him a net . drive it out of business by preventing fundraising so Pfizer could buy it on the cheap. His brother-in-law, Ugur Bayar, the CEO of Credit Suisse Turkey.
Healthcare stocks, especially the biotech segment, and related exchange traded This effectively gives smaller companies a more meaningful contribution to the .. Amgen's anti-cholesterol drug, which Credit Suisse analyst Alethia Young . Gilead - we think it will be difficult for the company to guide the HCV business as.
Credit Suisse downgraded Gilead Sciences to Neutral and lowered its price target, citing increased competition for hepatitis C drugs.